CoChat

Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis

Open access
Patel, Siddharth M., Kang, Yu Mi, Im, KyungAh, Neuen, Brendon L., Anker, Stefan D., Bhatt, Deepak L., Butler, Javed, Cherney, David Z.I., Claggett, Brian L., Fletcher, Robert A., Herrington, William G., Inzucchi, Silvio E., Jardine, Meg J., Mahaffey, Kenneth W., McGuire, Darren K., McMurray, John J.V., Neal, Bruce, Packer, Milton, Perkovic, Vlado, Solomon, Scott D., Staplin, Natalie, Vaduganathan, Muthiah, Wanner, Christoph, Wheeler, David C., Zannad, Faiez, Zhao, Yujie, Heerspink, Hiddo J.L., Sabatine, Marc S., Wiviott, Stephen D. · 2024 · Circulation
Cited by 198

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) consistently improve heart failure and kidney-related outcomes; however, effects on major adverse cardiovascular events (MACE) across different patient populations are less clear. METHODS: This was a collaborative trial-level meta-analysis from the SGLT2i Meta-analysis Cardio-Renal Trialists Consortium, which includes all phase 3, placebo-controlled, outcomes trials of SGLT2i across 3 patient populations (patients with diabetes at high risk for atherosclerotic cardiovascular disease, heart failure [HF], or chronic kidney disease). The outcomes of interest were MACE (composite of cardiovascular death, myocardial infarction , or stroke), individual components of MACE (inclusive of fatal and nonfatal events), all-cause mortality, and death subtypes. Effect estimates for SGLT2i versus placebo were meta-analyzed across trials and examined across key subgroups (established atherosclerotic cardiovascular disease, previous myocardial infarction, diabetes, previous HF, albuminuria, chronic kidney disease stages, and risk groups). RESULTS: A total of 78 607 patients across 11 trials were included: 42 568 (54.2%), 20 725 (26.4%), and 15 314 (19.5%) were included from trials of patients with diabetes at high risk for atherosclerotic cardiovascular disease, HF, or chronic kidney disease, respectively. SGLT2i reduced the rate of MACE by 9% (hazard ration [HR], 0.91 [95% CI, 0.87–0.96], P <0.0001) with a consistent effect across all 3 patient populations ( I 2 =0%) and across all key subgroups. This effect was primarily driven by a reduction in cardiovascular death (HR, 0.86 [95% CI, 0.81–0.92], P <0.0001), with no significant effect for myocardial infarction in the overall population (HR, 0.95 [95% CI, 0.87–1.04], P =0.29), and no effect on stroke (HR, 0.99 [95% CI, 0.91–1.07], P =0.77). The benefit for cardiovascular death was driven primarily by reductions in HF death and sudden cardiac death (HR, 0.68 [95% CI, 0.46–1.02] and HR, 0.86 [95% CI, 0.78–0.95], respectively) and was generally consistent across subgroups, with the possible exception of being more apparent in those with albuminuria ( P interaction =0.02). CONCLUSIONS: SGLT2i reduce the risk of MACE across a broad range of patients irrespective of atherosclerotic cardiovascular disease, diabetes, kidney function, or other major clinical characteristics at baseline. This effect is driven primarily by a reduction of cardiovascular death, particularly HF death and sudden cardiac death, without a significant effect on myocardial infarction in the overall population, and no effect on stroke. These data may help inform selection for SGLT2i therapies across the spectrum of cardiovascular-kidney-metabolic disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.124.069568

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 8

  1. 10.1056/NEJMoa2030186 · DOI · Paper page
  2. 10.1038/ki.2013.444 · DOI · Paper page
  3. 10.1016/S2213-8587(13)70050-0 · DOI · Paper page
  4. 10.1016/j.diabet.2023.101500 · DOI
  5. 10.1161/STROKEAHA.119.027759 · DOI · Paper page
  6. 10.1161/CIRCULATIONAHA.116.024637 · DOI
  7. 10.1056/EVIDoa2300286 · DOI · Paper page
  8. 10.1016/j.jacc.2023.04.034 · DOI

Cited by

See all 198

Metadata

Authors
Patel, S. M., Kang, Y. M., Im, K., Neuen, B. L., Anker, S. D., Bhatt, D. L., Butler, J., Cherney, D. Z. I., Claggett, B. L., Fletcher, R. A., Herrington, W. G., Inzucchi, S. E., Jardine, M. J., Mahaffey, K. W., McGuire, D. K., McMurray, J. J. V., Neal, B., Packer, M., Perkovic, V., Solomon, S. D., Staplin, N., Vaduganathan, M., Wanner, C., Wheeler, D. C., Zannad, F., Zhao, Y., Heerspink, H. J. L., Sabatine, M. S., & Wiviott, S. D.
Venue
Circulation
Published
2024-06-04
Volume
149
Issue
23
Pages
1789-1801
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W4394061861
Cited by
198
References
21
FWCI
53.81
Type
journal article
Language
en
Open access
hybrid
Licence
creativecommons.org/licenses/by-nc-nd/4.0/ (tdm)
Funders
  • HHS | National Institutes of Health (T32HL007604)
  • Australian National Health and Medical Research Council (Emerging Leader Investigator Grant (grant number 2026621))
  • HHS | NIH | NIDDK | Division of Diabetes, Endocrinology, and Metabolic Diseases (5T32DK007529)
  • Boehringer Ingelheim
  • AstraZeneca United States
  • Auris | J&J | Janssen Research and Development
  • Merck

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.